Amplia is pleased to announce that it has entered into a new research collaboration with Korean preclinical drug screening company @Next&Bio.
Headquartered in Seoul, Korea, Next& Bio have developed a unique drug screening capability in patient-derived cancer cells, allowing drugs to be tested under conditions that closely resemble the patient’s cancer environment, thereby better predicting how effectively drugs will act against the cancer.
The collaboration will explore the activity of Amplia’s FAK inhibitors against patient-derived pancreatic cancer cells that harbour known oncogenic mutations. Specifically, the Company is interested in exploring potential synergistic activity of the Company’s FAK inhibitors with a new class of drugs currently in development that inhibit the potent oncogene kRas. These drugs have the potential to be used in the treatment of pancreatic cancer in coming years.
The Company’s CEO and Managing Director, Dr Chris Burns, commented:
“To be able to test our FAK inhibitors in these well-characterised patient-derived cell systems, gives us the chance to explore the activity of our compounds in combination with targeted therapies such as kRas inhibitors. This in turn opens up new commercial opportunities for our FAK inhibitors to be used in combination with drug classes currently in clinical development for pancreatic cancer, in addition to the chemotherapy combination currently being investigated in the ACCENT trial.”
Click to read the ASX release.
